A laboratory report for the ARISk® Autism Risk Assessment Test is generated for each patient by IntegraGen following the receipt and testing of an appropriate DNA sample. This report is sent to the ordering physician 2 to 4 weeks following receipt fo the DNA sample.
The results report provides the following information for the individual tested:
Results should be interpreted only in conjunction with the patient’s clinical presentation. The ARISk Test does not diagnose autism. The results associated with the ARISk Test are only valid for individuals who have at least one sibling who has been diagnosed with autism at are based on a sibling recurrence rate of 26% in males and 9.6% in females.
To see a SAMPLE REPORT.
* Since the ARISk Test does not rule out ASD for children who are identified as having no change in risk or a decreased risk of autism, and since children who have a sibling with ASD are at higher risk compared to the general population, they should continue to be monitored for signs of developmental delay or ASD in line with the most recent guidelines published by the American Academy of Pediatrics.
To contact one of our genetic counselors with questions regarding the results report for the ARISk Test, please call 1-877-992-7475 (99ARISK), option #1
The U.S. Food and Drug Administration (FDA) has not approved or cleared this test. However, FDA approval or clearance is currently not required for clinical use of this test. Test results are not intended to be used as the sole means for clinical diagnosis or patient management decision
1Ozonoff S, et. al. Recurrence risk for autism spectrum disorders: a Baby Siblings
Research Consortium Study. Pediatrics. 2011; 128 (3):e488-95.